Study supports FDG-PET for assessing MCI

04/8/2013 | InternalMedicineNews.com (free registration)

A study comparing two sets of criteria for determining short- to mid-term incident Alzheimer's dementia among people with mild cognitive impairment found that FDG-PET presented as the strongest single positive predictive biomarker for short-term incident cases. The criteria studied were those published by an International Working Group in 2007 and by the National Institute on Aging and the Alzheimer's Association in 2011. The review involved an analysis of 73 patients from multiple centers.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
FDA/Post Drug Approval Attorney
Quarles & Brady
Washington, DC
Vice President for Product Delivery
National Committee for Quality Assurance
Washington, DC
SENIOR REGULATORY AFFAIRS SPECIALIST - 13000006XJ
Abbott
Oakland, CA
FDA/Device Technology Attorney
Quarles & Brady
Washington, DC
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC